QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Jonathan B. Rome Named COO Of Boston Therapeutics, Inc. (BTHE) 0 comments
    Nov 14, 2012 10:13 AM | about stocks: BTHE

    Yesterday, Boston Therapeutics announced that Mr. Jonathan B. Rome has been named as its Chief Operating Officer.

    David Platt, Ph.D., Boston's CEO, remarked, "Jonathan Rome has more than 30 years' experience and success in the sales, marketing and distribution of pharmaceutical products and developing collaborations around the world. Jonathan is an excellent choice to commercialize SUGARDOWN® and to lead the filing of an ANDA to market BTI-7."

    Mr. Rome was the Founder, President, and CEO of ThePharmaNetwork, LLC, which was focused on pharmaceutical portfolio development, licensing, sales, marketing, and distribution of pharmaceuticals and APIs as well as sales, marketing, and distribution of finished products under the Ascend Laboratories, LLC label to all major U.S. customers. Mr. Rome was also a founder of Beijing-based AlliancePharm LLC, a founder of Shanghai-based TPN China, Inc., and a founder of Rome, Italy-based TPN Italia. Mr. Rome specializes in collaborations, global supply chain, sales and marketing, licensing, and has extensive outsourcing experience through a network that spans five continents.

    "I am excited about joining Boston Therapeutics," said Jonathan Rome. "The elements for success are here: excellent complex carbohydrate chemistry, products to address unmet medical needs in a very large diabetes market worldwide and a talented and dedicated team. I am confident we can be successful and take the Company to the next level."

    Mr. Rome will be in charge of accelerating the commercialization of SUGARDOWN® and filing an Abbreviated New Drug Application ("ANDA") for BTI-7, a new chewable dosage form of the diabetes drug metformin hydrochloride. SUGARDOWN® is a non-systemic chewable dietary supplement tablet that controls post-meal blood glucose.

    For more information on Boston Therapeutics, visit bostonti.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: BTHE
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.